Response to Keytruda (pembrolizumab) better in older patients, study suggests
Last updated: 01 November 2019
You can legally access new medicines, even if they are not approved in your country.
Learn more »
Older melanoma patients respond better to the anti-PD-1 immunotherapy Keytruda (pembrolizumab), according to new data from a multinational study. Researchers believe these differences are due to a reduced immunosuppressive tumor environment in older patients.
Find out further details on the study and its implications in this Immuno-Oncology news article.
